Dr Leon Kiriaev is a Research Officer in the Muscle Research Group at the Murdoch Children's Research Institute. In 2022 he obtained his PhD from the faculty of medicine at Western Sydney University/UNSW where he investigated the role of branched skeletal muscle fibres in the pathogenesis of Duchenne Muscular Dystrophy and the influence of ACTN3 deficiency as a genetic modifier.
Incorporating contractile physiology, imaging and molecular biology techniques, he has helped investigate various genetic mutations that impact muscle performance (ACTN3, PYROXD1, NMNAT1, Duchenne, dysferlinopathy) and explore the effects of treatment strategies (NAC, minocycline, notexin, ASO therapies, DHT) to help understand and develop therapeutic targets for neuromuscular diseases.
Currently, his research focus is on modelling neuromuscular diseases to investigate therapeutic strategies and the effects of ACTN3 R577X deficiency on glycogen metabolism and metabolic health.
Dr Leon Kiriaev is a Research Officer in the Muscle Research Group at the Murdoch Children's Research Institute. In 2022 he obtained his PhD from the faculty of medicine at Western Sydney University/UNSW where he investigated the role of branched skeletal muscle fibres in the pathogenesis of Duchenne Muscular Dystrophy and the influence of ACTN3 deficiency as a genetic modifier.
Incorporating contractile physiology, imaging and molecular biology techniques, he has helped investigate various genetic mutations that impact muscle performance (ACTN3, PYROXD1, NMNAT1, Duchenne, dysferlinopathy) and explore the effects of treatment strategies (NAC, minocycline, notexin, ASO therapies, DHT) to help understand and develop therapeutic targets for neuromuscular diseases.
Currently, his research focus is on modelling neuromuscular diseases to investigate therapeutic strategies and the effects of ACTN3 R577X deficiency on glycogen metabolism and metabolic health.